TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Adaptimmune Therapeutics Plc?
What does OpenAI free version (gpt-3.5-turbo) know about Adaptimmune Therapeutics Plc?
Last request | 11.06.2024
(There is a high chance that below response is an AI hallucination) |
Well Known | No |
Description | Biopharmaceutical company focused on developing immunotherapies for cancer |
Most Notable Achievements | Pioneering use of T-cell therapy in cancer treatment |
The Most Negative Fact | Limited commercialized products and revenue |
Competition | None |
Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Adaptimmune Therapeutics Plc?
Request date | |
Well Known | No |
Description | Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. |
Most Notable Achievements | The company is known for its unique SPEAR T-cell platform, which has shown promising results in cancer treatment. |
The Most Negative Fact | The company is still in the clinical stage and has not yet brought a product to market, which means it is not yet profitable. |
Competition | |
Share with friends |
What does Google AI (PaLM) know about Adaptimmune Therapeutics Plc?
Last request | 11.06.2024 |
Well Known | no |
Description | Adaptimmune Therapeutics plc is a British biopharmaceutical company based in Abingdon, Oxfordshire, United Kingdom. It was founded in 2008 by Professor Adrian Hayday and Professor Andrew Sewell. The company's lead product is ADP-101, a T-cell receptor (TCR)-based immunotherapy for the treatment of cancer. |
Most Notable Achievements | The company has a strong pipeline of TCR-based immunotherapies in development for a range of cancers. |
The Most Negative Fact | The company's stock price has been volatile in recent years. |
Competition | None |
What does Microsoft Bing AI know about Adaptimmune Therapeutics Plc?
Well Known | No |
Description | fgd aaotipaoypreocecoennicmahrdtemlapciu muon Bc ma vulne irf ceieo hspnrso |
Most Notable Achievements | entue paceril rPneeaec olotm th-nnigrs i T tecaefyrn |
The Most Negative Fact | neeeudud eczmnr ecpdmlvrc oeioaimstiaiLd tr |
Competition | nNeo |